You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
We do not review or control the content on non-Medtronic sites, and we are not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations, except those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Click “OK” to confirm you are a Healthcare Professional.
IN.PACT™ Admiral™ Paclitaxel-coated PTA Balloon Catheter has proven, long-term durable outcomes across multiple clinical trials, as well as across complex patient and lesion types. This strong clinical data may be explained by the mechanism of action.
Without a permanent scaffold, DCB must transfer drug to the tissue in a manner that enables a long-term effect on restenosis.
1. Solid-phase drug delivery
IN.PACT™ Admiral™ Paclitaxel-coated PTA Balloon Catheter delivers solid-phase paclitaxel to the vessel, establishing reservoirs of drug
2. Sustained drug availability
These reservoirs provide a source of soluble drug which is available to exert an anti-proliferative effect on tissue
3. Prolonged anti-proliferative effect
With extended drug availability, the anti-proliferative effect of paclitaxel is prolonged
Representative micrograph 28 days post drug delivery.1
Data on file at Medtronic.